Edition:
United Kingdom

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

2.86USD
20 Aug 2019
Change (% chg)

$0.02 (+0.70%)
Prev Close
$2.84
Open
$2.84
Day's High
$2.88
Day's Low
$2.77
Volume
147,083
Avg. Vol
262,128
52-wk High
$3.86
52-wk Low
$1.55

Summary

Name Age Since Current Position

Garo Armen

66 1994 Chairman of the Board, Chief Executive Officer, Founder, Director

Jennifer Buell

2018 Chief Operating Officer

Alexander Duncan

2017 Chief Technology Officer and Head - Research

Christine Klaskin

52 2018 Chief Accounting Officer, Vice President - Finance

Evan Kearns

2018 Vice President, General Counsel, Secretary

Don Vidic

2019 Vice President, Head of Commercial

Timothy Wright

61 2009 Lead Independent Director

Brian Corvese

61 2007 Independent Director

Allison Jeynes-Ellis

53 2018 Independent Director

Wadih Jordan

84 2003 Independent Director

Ulf Wiinberg

60 2016 Independent Director

Biographies

Name Description

Garo Armen

Dr. Garo H. Armen, Ph.D., is the founder, Chairman of the Board and Chief Executive Officer of Agenus Inc. Dr. Armen is Chairman and Chief Executive Officer of Agenus Inc., which he co-founded in 1994. Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as years of expertise in the financial and biopharmaceutical arenas. From mid-2002 through 2004, he was Chairman of the Board of Directors for the biopharmaceutical company Elan Corporation, plc which he helped restructure. Dr. Armen currently serves as non-executive Chairman of the Board of Directors of Protagenic Therapeutics, Inc., a publicly held biotechnology company. Dr. Armen is also the founder and Chairman of the Children of Armenia Fund, a philanthropic organization established in 2000 that is dedicated to the positive development of the children and youth of rural Armenia. He holds a Ph.D. degree in physical organic chemistry from the City University of New York.

Jennifer Buell

Dr. Jennifer S. Buell is Chief Operating Officer of the Company. Since joining Agenus in 2013, Dr. Buell has served as the Head of Global R&D operations, Head of Research, and most recently as Chief Communications and External Affairs Officer. During her tenure, Jen helped advance the expansion of Agenus from a neoantigen vaccine company to a global, fully-integrated platform company with a unique pipeline of immune modulating antibodies, cancer vaccines, adjuvants, and adoptive cell therapies. Today, Agenus has major collaborations with Merck and Incyte, a demonstrated track record of delivering on operational commitments, and has outpaced pharma in delivering new discoveries to the clinic. In her new role, Dr. Buell will assume responsibility for Research, Clinical Development, Manufacturing, Commercial Operations, and relevant supportive functions.

Alexander Duncan

Dr. Alexander Duncan is the Chief Technology Officer and Head of Research of Agenus Inc.

Christine Klaskin

Ms. Christine M. Klaskin is the Principal Accounting Officer of Agenus Inc. Ms. Klaskin has been Vice President, Finance since October 2006. Since joining Agenus Inc. in 1996 as finance manager, Ms. Klaskin has held various positions within the finance department and has been involved in all equity and debt offerings of the Company including its IPO. Ms. Klaskin is currently a member of the board of directors of American DG Energy Inc. Prior to joining Agenus, Ms. Klaskin was employed by Arthur Andersen as an audit manager. Ms. Klaskin received her Bachelor of Accountancy from The George Washington University.

Evan Kearns

Mr. Evan Kearns is the Vice President, General Counsel, Secretary of Agenus Inc, effective as of July 12, 2018. He first joined the Company in 2014 and previously served as the Company’s Vice President, Associate General Counsel. Prior to joining the Company, Mr. Kearns was with the law firm of Goodwin Procter LLP in Boston, MA, where he advised public and private companies in domestic and international transactions on corporate and securities law matters, merger, acquisition and financing transactions, corporate governance, and other general corporate matters. Mr. Kearns received a B.A. degree from Colby College magna cum laude and a J.D. degree from the University of Toledo College of Law magna cum laude.

Don Vidic

Mr. Don Vidic is Vice President, Head of Commercial of the Company. Don Vidic is an industry veteran with more than 30 years of expertise in specialty pharma distribution, managed care, as well as physician and pharmacy services. Prior to joining Agenus, Don served as the Chief Pharmacy and Growth Officer at Walgreens Boots Alliance and as the General Manager and VP at McKesson, currently the largest oncology specialty pharma, where he managed all trade, managed care, physician sales and pharmacy services.

Timothy Wright

Mr. Timothy R. (Tim) Wright is an Independent Director of Agenus Inc. Mr. Wright has been the Executive Vice President, Business Development, Strategy and Innovation at Teva Pharmaceuticals Industries Ltd since April 2015. Mr. Wright also serves as chairman of The Ohio State University Comprehensive Cancer Center Drug Development Institute, and director of the Ohio State University Innovation Foundation. From July 2011 to July 2012, Mr. Wright served as Chairman, Interim CEO, and a member of the Board of Directors of Curaxis Pharmaceuticals Corporation, a research based company dedicated to finding cures for age-related diseases, including Alzheimer’s disease and cancer. Prior to Mr. Wright’s tenure at Curaxis, the company had been experiencing financial difficulties and, as a result, Curaxis filed for Chapter 11 bankruptcy in July 2012. Prior to that, Mr. Wright served as President of the Imaging Solutions and Pharmaceutical Products Sector of Covidien. Mr. Wright brings to our Board over 29 years of global pharmaceutical industry experience in general management, product development, and commercialization as well as business restructuring and transaction experience. Beginning in April 2004, Mr. Wright was interim CEO, President and a member of the Board of Directors of AAI Pharma, a hybrid pharmaceutical, drug delivery/manufacturing, and global clinical research organization. Upon the sale of AAI Pharma’s pharmaceutical assets to Xanodyne Pharmaceuticals Inc., Mr. Wright transitioned to Chief Operating Officer at Xanodyne Pharmaceuticals Inc., a role he maintained until May 2006. Mr. Wright was also President of Elan Bio-Pharmaceuticals and has held several senior management positions with Cardinal Health Inc. and Dupont Merck Pharmaceutical Company. Over his career, Mr. Wright has served on nine Boards of Directors, five in North America and four in Europe and Asia. Mr. Wright earned his bachelor’s degree from The Ohio State University.

Brian Corvese

Mr. Brian Corvese is an Independent Director of Agenus Inc. Since 1999, Mr. Corvese has been the President and Founder of Vencor Capital (“Vencor”), a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to working at Vencor, Mr. Corvese worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management (“Chancellor”), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert (“Drexel”) as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the Board of Directors of the National Telecommunications Corporation, based in Cairo, Egypt. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School. With over 30 years of experience in the financial industry, Mr. Corvese brings substantial financial expertise to our Board.

Allison Jeynes-Ellis

Dr. Allison M. Jeynes-Ellis is Director of the Company. Dr. Jeynes-Ellis joins the Board with over 25 years of senior leadership experience in the pharmaceutical industry. Dr. Jeynes-Ellis is the Chief Executive Officer of Avillion LLP (“Avillion”), a London-based drug development company. Prior to her current position as CEO, Dr. Jeynes-Ellis served as Avillion’s Chief Medical Officer from December 2012 to January 2014. Before her tenure at Avillion, Dr. Jeynes-Ellis worked in senior roles at Wyeth, Bristol-Myers Squibb, and Novartis. Her previous affiliations also include Cambridge Antibody Technology and Genentech, government bodies and medical charities. She has managed teams focusing on global clinical development projects that have led to drug approvals in Europe and the United States, across a range of therapeutic areas. Dr. Jeynes-Ellis currently serves as a non-executive director of the Health Research Authority, an executive non-departmental public body of the Department of Health in the United Kingdom. The Board has deemed that Dr. Jeynes-Ellis is a highly qualified candidate to serve on the Board.

Wadih Jordan

Mr. Wadih (Bill) Jordan is an Independent Director of Agenus Inc. Mr. Jordan was most recently the founder and President of NearEast Enterprise, L.L.C. from 2011 to April 2015, a company that marketed pharmaceuticals in Near East markets, including Lebanon, Turkey, Saudi Arabia, Egypt, and the Gulf countries. From 1995 to 2011, Mr. Jordan served as the President of NearEast Pharma LLC, a company that provided pharmaceutical, biotechnology and equipment for pharmaceutical industries to the Near East and Middle East markets. From 1993 to 1995, Mr. Jordan served as a Vice President of Cyanamid International, a research-based life sciences company, and from 1976 to 1993, Mr. Jordan served as a Managing Director within Cyanamid International. Since December 2003, Mr. Jordan has been a trustee of the Board of Directors of the Lebanese American University, located in Beirut, Lebanon, and incorporated under the Board of Regents in New York State. Mr. Jordan received a bachelor’s degree in agriculture at the American University of Beirut, Lebanon, and a certificate in international business from Columbia University. Mr. Jordan brings to our Board years of expertise in both the biotechnology/pharmaceutical and international arenas.

Ulf Wiinberg

Mr. Ulf Wiinberg is an Independent Director of Agenus Inc. Mr. Wiinberg has almost 20 years of senior leadership experience, most recently serving as Chief Executive Officer of H. Lundbeck A/S (“Lundbeck”) from June 2008 to December 2014. Lundbeck is a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the boards of several health care industry associations and held multiple executive roles at Wyeth, one of the world’s largest research-driven pharmaceutical companies that was acquired by Pfizer in 2009. He served as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK, and in various commercial positions. Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Avillion LLP (Chairman), a London-based drug development company, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, and Alfa Laval AB, a Swedish industrial company. Mr. Wiinberg brings to our Board years of experience in the biotechnology, pharmaceutical and healthcare industries internationally.

Basic Compensation

Name Fiscal Year Total

Garo Armen

2,567,840

Jennifer Buell

986,467

Alexander Duncan

833,264

Christine Klaskin

497,477

Evan Kearns

--

Don Vidic

--

Timothy Wright

218,702

Brian Corvese

257,577

Allison Jeynes-Ellis

167,782

Wadih Jordan

113,702

Ulf Wiinberg

195,077
As Of  31 Dec 2018